The GOT-IT recommendations consider the complexity of tasks associated with bridging the gap between basic science research findings and the identification of clinically effective products. The guidelines suggest the need for an environment where academic research teams focusing on newly identified drug targets can connect with experienced and qualified expert industry teams in support of successful drug discovery and development.
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Sage Bionetworks announce the winners of the BEAT-PD DREAM Challenge. BEAT-PD (Biomarker and Endpoint Assessment to Track Parkinson’s Disease) is a data challenge designed to benchmark new methods to predict Parkinson’s disease severity in patients in their homes. MJFF and Sage partnered with Evidation Health, Northwestern University, Radboud University Medical Center, and the BRAINCommons to host the BEAT-PD Challenge.
At the beginning of 2020, the Michael J Fox Foundation (MJFF) in coordination with Sage Bionetworks and the BRAINCommons (BC) held The Biomarker and Endpoint Assessment to Track Parkinson's Disease (BEAT-PD) Challenge. Participants were provided with raw sensor (accelerometer and gyroscope) time series data recorded during the course of daily living, and were asked to predict individuals' medication state and symptom severity.
These data are now available to qualified researchers once [...]
On September 24, 2019, Cohen Veterans Bioscience CEO & President Dr. Magali Haas and CIO Dr. Lee Lancashire participated in “Neuroscience Data in the Cloud”, a workshop hosted by The National Academies of Science, Engineering and Medicine.
The Proceedings from Neuroscience Data in the Cloud are now available online.
The Michael J. Fox Foundation (MJFF) and Sage Bionetworks launched the Biomarker and Endpoint Assessment to Track Parkinson’s Disease (BEAT-PD) DREAM Challenge, in partnership with Evidation Health, Northwestern University, Radboud University Medical Center and BRAINCommons.
A recent article by Todd Sherer, PhD, CEO of the Michael J. Fox Foundation for Parkinson’s Research (MJFF), highlighted the collaboration between the BRAINCommons and MJFF in their Parkinson’s Progression Markers Initiative (PPMI) study.